140 related articles for article (PubMed ID: 21077414)
1. Voice related quality of life after botulinum toxin injection for spasmodic dysphonia.
Gama AC; Menezes LN; Maia AA; Rezende Neto AL; Oliveira JB
Rev Laryngol Otol Rhinol (Bord); 2010; 131(1):39-44. PubMed ID: 21077414
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the VHI, VHI-10, and V-RQOL for measuring the effect of botox therapy in adductor spasmodic dysphonia.
Morzaria S; Damrose EJ
J Voice; 2012 May; 26(3):378-80. PubMed ID: 20951552
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal effects of botulinum toxin injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia.
Hogikyan ND; Wodchis WP; Spak C; Kileny PR
J Voice; 2001 Dec; 15(4):576-86. PubMed ID: 11792036
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin treatment of adductor spasmodic dysphonia: longitudinal functional outcomes.
Novakovic D; Waters HH; D'Elia JB; Blitzer A
Laryngoscope; 2011 Mar; 121(3):606-12. PubMed ID: 21298641
[TBL] [Abstract][Full Text] [Related]
5. Combined modality treatment of adductor spasmodic dysphonia.
Silverman EP; Garvan C; Shrivastav R; Sapienza CM
J Voice; 2012 Jan; 26(1):77-86. PubMed ID: 21292439
[TBL] [Abstract][Full Text] [Related]
6. Clinical practice guideline: hoarseness (dysphonia).
Schwartz SR; Cohen SM; Dailey SH; Rosenfeld RM; Deutsch ES; Gillespie MB; Granieri E; Hapner ER; Kimball CE; Krouse HJ; McMurray JS; Medina S; O'Brien K; Ouellette DR; Messinger-Rapport BJ; Stachler RJ; Strode S; Thompson DM; Stemple JC; Willging JP; Cowley T; McCoy S; Bernad PG; Patel MM
Otolaryngol Head Neck Surg; 2009 Sep; 141(3 Suppl 2):S1-S31. PubMed ID: 19729111
[TBL] [Abstract][Full Text] [Related]
7. Assessing the effectiveness of botulinum toxin injections for adductor spasmodic dysphonia: clinician and patient perception.
Braden MN; Johns MM; Klein AM; Delgaudio JM; Gilman M; Hapner ER
J Voice; 2010 Mar; 24(2):242-9. PubMed ID: 19481417
[TBL] [Abstract][Full Text] [Related]
8. Considerations for initial dosing of botulinum toxin in treatment of adductor spasmodic dysphonia.
Rosow DE; Parikh P; Vivero RJ; Casiano RR; Lundy DS
Otolaryngol Head Neck Surg; 2013 Jun; 148(6):1003-6. PubMed ID: 23535709
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal effects of Botox injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia: part II.
Rubin AD; Wodchis WP; Spak C; Kileny PR; Hogikyan ND
Arch Otolaryngol Head Neck Surg; 2004 Apr; 130(4):415-20. PubMed ID: 15096423
[TBL] [Abstract][Full Text] [Related]
10. Nonpharmacologic effects of botulinum toxin on the life quality of patients with spasmodic dysphonia.
Anari S; Carding PN; Hawthorne MR; Deakin J; Drinnan MJ
Laryngoscope; 2007 Oct; 117(10):1888-92. PubMed ID: 17690610
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal follow-up of adductor spasmodic dysphonia patients after botulinum toxin injection: quality of life results.
Paniello RC; Barlow J; Serna JS
Laryngoscope; 2008 Mar; 118(3):564-8. PubMed ID: 18216744
[TBL] [Abstract][Full Text] [Related]
12. Relationship of laryngeal botulinum toxin dosage to patient age, vitality, and socioeconomic issues.
Young DL; Halstead LA
J Voice; 2014 Sep; 28(5):614-7. PubMed ID: 24954039
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of spasmodic dysphonia with botulinum toxin].
Klap P; Marion MH; Perrin A; Fresnel-Elbaz E
Ann Otolaryngol Chir Cervicofac; 1991; 108(8):477-82; discussion 482-3. PubMed ID: 1789624
[TBL] [Abstract][Full Text] [Related]
14. Effect of Botulinum Toxin and Surgery among Spasmodic Dysphonia Patients.
van Esch BF; Wegner I; Stegeman I; Grolman W
Otolaryngol Head Neck Surg; 2017 Feb; 156(2):238-254. PubMed ID: 27803079
[TBL] [Abstract][Full Text] [Related]
15. A rare case of laryngeal dystonia associated with neurosyphilis: Response to botulinum toxin injection.
Ho KH; Wright CC; Underbrink MP
Laryngoscope; 2011 Jan; 121(1):147-9. PubMed ID: 21154825
[TBL] [Abstract][Full Text] [Related]
16. Spasmodic dysphonia: a seven-year audit of dose titration and demographics in the Indian population.
Nerurkar NK; Banu TP
J Laryngol Otol; 2014 Jul; 128(7):649-53. PubMed ID: 24999662
[TBL] [Abstract][Full Text] [Related]
17. [Voice-related quality of life: structure, validity and factors of the German questionnaire].
Schwanfelder C; Eysholdt U; Rosanowski F; Graessel E
Folia Phoniatr Logop; 2008; 60(5):241-8. PubMed ID: 18728369
[TBL] [Abstract][Full Text] [Related]
18. Pharyngeal Dystonia Mimicking Spasmodic Dysphonia.
Shi LL; Simpson CB; Hapner ER; Jinnah HA; Johns MM
J Voice; 2018 Mar; 32(2):234-238. PubMed ID: 28651822
[TBL] [Abstract][Full Text] [Related]
19. The point-touch technique for botulinum toxin injection in adductor spasmodic dysphonia: quality of life assessment.
Morzaria S; Damrose EJ
J Laryngol Otol; 2011 Jul; 125(7):714-8. PubMed ID: 21524329
[TBL] [Abstract][Full Text] [Related]
20. Liquid-type Botulinum Toxin Type A in Adductor Spasmodic Dysphonia: A Prospective Pilot Study.
Cha W; Jang JY; Wang SG; Kang JH; Jo MG
J Voice; 2017 May; 31(3):378.e19-378.e24. PubMed ID: 27520509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
